BMY vs. AMGN, EXEL, GILD, MRNA, VRTX, ABBV, JNJ, LLY, MRK, and PFE
Should you be buying Bristol Myers Squibb stock or one of its competitors? The main competitors of Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.
Bristol Myers Squibb vs. Its Competitors
Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.
Amgen presently has a consensus target price of $309.42, indicating a potential upside of 5.82%. Bristol Myers Squibb has a consensus target price of $57.14, indicating a potential upside of 31.23%. Given Bristol Myers Squibb's higher probable upside, analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.
In the previous week, Amgen had 8 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 60 mentions for Amgen and 52 mentions for Bristol Myers Squibb. Amgen's average media sentiment score of 1.09 beat Bristol Myers Squibb's score of 1.01 indicating that Amgen is being referred to more favorably in the media.
Amgen has a net margin of 18.96% compared to Bristol Myers Squibb's net margin of 10.58%. Amgen's return on equity of 174.71% beat Bristol Myers Squibb's return on equity.
Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.7%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
76.5% of Amgen shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.7% of Amgen shares are held by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Amgen has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Bristol Myers Squibb has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Summary
Amgen beats Bristol Myers Squibb on 14 of the 20 factors compared between the two stocks.
Get Bristol Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol Myers Squibb Competitors List
Related Companies and Tools
This page (NYSE:BMY) was last updated on 10/14/2025 by MarketBeat.com Staff
